Universiteit Leiden

nl en

Antonius Johannes Rabelink

Professor Internal Medicine, in particular nephrology

Name
Prof.dr. A.J. Rabelink
Telephone
+31 71 526 2148
E-mail
a.j.rabelink@lumc.nl
ORCID iD
0000-0001-6780-5186

Ton Rabelink is Professor of Internal Medicine and Nephrologist at the LUMC. Here, he also heads the department of Internal Medicine. He is Leiden Node Director of the Novo Nordisk Foundation for Stem Cell Medicine, reNEW and figurehead of the theme Regenerative Medicine within the Dutch National Science Agenda. In addition, he’s CSO and co-founder of the LUMC affiliate NecstGen - a non-for-profit Good Manufacturing Practice facility for cell and gene therapy based at Leiden Bio Science Park. Rabelink is co-founder and was kidney-moonshot leader of the public private regenerative medicine consortium RegMedXB, and Chair of the LUMC and Leiden University for the theme Regenerative Medicine. He led the EU Horizon consortium STELLAR, which aimed at developing cellular therapies for kidney disease. In 2024 he was awarded an ERC advanced grant (SPARK) to study the fundamental mechanisms of kidney regeneration.

More information about Antonius Johannes Rabelink

Ton Rabelink is Professor of Internal Medicine and Nephrologist at the LUMC. Here, he also heads the department of Internal Medicine. He is Leiden Node Director of the Novo Nordisk Foundation for Stem Cell Medicine, reNEW and figurehead of the theme Regenerative Medicine within the Dutch National Science Agenda. In addition, he’s CSO and co-founder of the LUMC  affiliate NecstGen - a non-for-profit Good Manufacturing Practice facility for cell and gene therapy based at Leiden Bio Science Park.

Rabelink is co-founder and was  kidney-moonshot leader of the public private regenerative medicine consortium RegMedXB, and Chair of the LUMC and Leiden University for the theme Regenerative Medicine. He led the EU Horizon consortium STELLAR, which aimed at developing cellular therapies for kidney disease.  In 2024 he was awarded an ERC advanced grant (SPARK) to study the fundamental mechanisms of kidney regeneration.

Chronic kidney diseases

Chronic kidney diseases are a major global health challenge and transplantation still is the only option for patients with end-stage renal failure to regain a reasonable quality of life. Because suited donor organs are scarce, our research aims to grow and regenerate kidney tissue ex vivo which can be used as an alternative source of transplantable kidney tissue in the future.

Towards this goal, we study renal biology in health, disease and regeneration with a specific focus on how renal cell metabolism and exchange of metabolites in the tissue microenvironment impact cell fate decisions towards differentiation, repair and injury. We combine our expertise in endothelial cell biology, human stem cell biology and state of the art multi-omics approaches to study this. Doing so, we not only aim to identify proteins and metabolites  with regulatory roles in processes as renal maturation, preservation and regeneration but will also get a better understanding on how we can manipulate the cellular metabolism to optimize these processes in our renal tissue models systems to develop new therapies that combat chronic kidney disease.

Academic career

Ton Rabelink received his MD PhD degree at Utrecht University. Here, he also completed his residency and fellowships in internal medicine and nephrology before joining the medical staff. He became a professor by special installment of the Dutch Kidney Foundation in 1998, after which he was installed as professor by Utrecht University in 2000. Subsequently, he was appointed chairman of medicine in the University Hospital Utrecht from 1999 to 2004.

In 2004, Ton Rabelink moved to Leiden University Medical Center where he chairs the department of Internal Medicine.

Professor Internal Medicine, in particular nephrology

  • Faculteit Geneeskunde
  • Divisie 2
  • Interne Geneeskunde
  • Nierziekten

Work address

LUMC Main Building
Albinusdreef 2
2333 ZA Leiden
Room number CQ-7

Contact

  • Necstgen Chief Scientific Officer
This website uses cookies.  More information.